News

Poor outcome for PBC patient with bullous pemphigoid


 

FROM THE REVISTA DE GASTROENTEROLOGIA DE MEXICO

References

A 45-year-old woman who was admitted with concurrent primary biliary cirrhosis or cholangitis (PBC) and bullous pemphigoid died 5 days after admittance, according to a case report from N.B. Guerra-Uribe, MD, and M.S. González-Huezo, MD.

The patient was admitted to the emergency department for dermatosis, which had been present for 21 days. The patient had also been diagnosed with PBC, which was in an advanced stage. Vesicular lesions had appeared on the right upper limb and disappeared spontaneously, only to reappear on the lower extremities. Examination revealed large blisters with a fibrin base and necrotic edges.

A skin biopsy showed that the lesions were subepidermal blisters with a superficial, mixed, perivascular inflammatory infiltrate consistent with bullous pemphigoid. During the hospitalization, the patient developed a catheter-related urinary tract infection, acute renal lesions, and spontaneous bacterial peritonitis. The patient developed septic shock due to the urinary tract infection and died 5 days after admittance.

“The unfortunate case of our patient reflects the delay in seeking medical attention that resulted in a fatal outcome. In addition, early disease onset is associated with a worse prognosis and a higher failed treatment rate,” the investigators wrote.

They reported having no relevant financial conflicts.

Find the full case report in the Revista De Gastroenterologia De Mexico (doi: 10.1016/j.rgmx.2015.08.004).

lfranki@frontlinemedcom.com

Recommended Reading

Anti-TNF therapy can continue for IBD patients with skin lesions
MDedge Dermatology
FDA approves treatment for chemotherapy ODs, life-threatening toxicities
MDedge Dermatology
Step therapy and biologics: An easier road ahead?
MDedge Dermatology
Biosimilar infliximab gains FDA Advisory Committee endorsement
MDedge Dermatology
Study: 2.6% of patients discharged from U.S. hospital used probiotics
MDedge Dermatology
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
MDedge Dermatology
Make informed treatment decisions about biosimilars
MDedge Dermatology
Study: TNF inhibitors improve extraintestinal IBD manifestations
MDedge Dermatology
Skin patch testing pinpoints dietary triggers of IBS
MDedge Dermatology
Updated Behçet’s disease recommendations expand biologic treatment
MDedge Dermatology